Personalized medicine for patients with asthma

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2, 2010, Pages 305-306

  Greenberger, Paul A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

adherence; Asthma; corticosteroid; polymorphisms; variability

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; OMALIZUMAB; SALBUTAMOL;

ASTHMA; CLINICAL TRIAL; EDITORIAL; FORCED EXPIRATORY VOLUME; GENE DELETION; GENE INSERTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MEDICAL RESEARCH; PHARMACOGENOMICS; PRIORITY JOURNAL; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 75849162449     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.11.038     Document Type: Editorial

References (22)

1. Hawkins G.A., Weiss S.T., and Bleecker E.R. Clinical consequences of ADRbeta2 polymorphisms. Pharmacogenomics 9 (2008) 349-358
2. Sharma S., Litonjua A.A., Tantisira K.G., Fuhlbrigge A.L., Szefler S.J., Strunk R.C., et al. Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program. J Allergy Clin Immunol 122 (2008) 921-928
3. Martin R.J., Szefler S.J., King T.S., Kraft M., Boushey H.A., Chinchilli V.M., et al. The predicting response to inhaled corticosteroid efficacy (PRICE) trial. J Allergy Clin Immunol 119 (2007) 73-80
4. Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske Jr. R.F., Strunk R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunology 115 (2005) 233-242
5. Knuffman J.E., Sorkness C.A., Lemanske Jr. R.F., Mauger D.T., Boehmer S.J., Martinez F.D., et al. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol 123 (2009) 411-416
6. Goleva E., Li L.B., Eves P.T., Strand M.J., Martin R.J., and Leung D.Y. Increased glucocorticoid receptor β alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 173 (2006) 607-616
7. Tantisira K.G., and Drazen J.M. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol 124 (2009) 422-427
8. Lima J.J., Zhang S., Grant A., Shao L., Tantisira K.G., Allayee H., et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 173 (2006) 379-385
9. Tantisira K.G., Lima J., Sylvia J., Klanderman B., and Weiss S.T. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics 19 (2009) 244-247
10. Niebauer K., Dewilde S., Fox-Rushby J., and Revicki D.A. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 96 (2006) 316-326
11. Greenberger P.A. Asthma. In: Grammer L.C., and Greenberger P.A. (Eds). Patterson's allergic diseases. 7th ed. (2009), Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia 333-388
12. Peters S.P., Jones C.A., Haselkorn T., Mink D.R., Valacer D.J., and Weiss S.T. Real world evaluation of asthma control and treatment (REACT): findings from a national web-based survey. J Allergy Clin Immunol 119 (2007) 1454-1461
13. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J.H., Pauwels R.A., et al. Can guideline-defined asthma control be achieved?: the Gaining Optimum Asthma Control study. Am J Respir Crit Care Med 170 (2004) 836-844
14. Flockhart D.A., and Bertilsson L. Clinical pharmacogenetics. In: Atkinson Jr. A.J., Abernethy D.R., Daniels C.E., Dedrick R.L., and Markey S.P. (Eds). Principles of clinical pharmacology. 2nd ed. (2007), Elsevier, Amsterdam 179-195
15. Sox H.C., and Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 151 (2009) 203-205
16. Naik A.D., and Peterson L.A. The neglected purpose of comparative-effectiveness research. N Engl J Med 360 (2009) 1929-1931
17. Szefler S.J., and Martin R.J. Lessons learned from variation in response to therapy in clinical trials. J Allergy Clin Immunol 125 (2010) 285-292
18. FitzGerald J.M., and Shahidi N. Achieving asthma control in patients with moderate disease. J Allergy Clin Immunol 125 (2010) 307-311
19. Kazani S., Wechsler M.E., and Israel E. The role of pharmacogenomics in improving the management of asthma. J Allergy Clin Immunol 125 (2010) 295-302
20. Moorman J.E., Rudd R.A., Johnson C.A., King M., Minor P., Bailey C., et al. National surveillance for asthma-United States, 1980-2004. MMWR Surveill Summ 56 SS08 (2007) 1-54
21. National Heart, Lung and Blood Institute, National Asthma Education and Prevention Program. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007 (2007), US Department of Health and Human Services, Bethesda (MD) NIH publication no. 07-4051
22. Global Initiative for Asthma. Global strategy for asthma management and prevention (1995 (updated 2006)), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda (MD). http://www.ginasthma.org Accessed October 28, 2009